These results yield novel insights for possible clinical investigation of targeted therapy for mutant CBL‐positive AML and suggest that therapies beneficial for mutant FLT3‐positive leukaemia may be similarly beneficial for mutant CBL‐positive leukaemia due to the similarities between the two leukaemia subtypes. The gene discussed is FLT3; the disease is acute myeloid leukemia.